ConductScience.org, home

Comparison · NCT02561702-b5f85ce2

Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Duration

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Duration. Trial comparisons, record NCT02561702-b5f85ce2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02561702-b5f85ce2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.50.150.85wilson
Risk in group 2000.49wilson
Risk difference, group 1 minus group 20.5-0.1020.85newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Mexiletine than on Placebo2from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Mexiletine
Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily~Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days~Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
24OG000
Group 2Placebo
Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily~Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days~Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
04OG001

Outcome

Type
PRIMARY
Title
Number of Participants With a Decrease in Cramp Duration
Description
Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used.
Time frame
120 minutes
Population

Source ClinicalTrials.gov

Trial

Title
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
NCT number
NCT02561702
Phases
PHASE2
Conditions
Charcot Marie Tooth Disease
Interventions
Placebo, Mexiletine
Lead sponsor
University of Rochester
Results first posted
2018-03-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02561702-b5f85ce2